ClinicalTrials.gg
RecruitingNCT07275242Updated Jan 15, 2026

A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor

A Phase 1 interventional study of SHR-A1811 Subcutaneous Injection and SHR-A1811 for Injection in Solid Tumor, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
107
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study is being conducted to evaluate the pharmacokinetics , safety, tolerability and efficacy in patients with solid tumor.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years of age;
  2. Solid Tumor confirmed by histology or cytology;
  3. score is 0 or 1;
  4. An expected survival of ≥ 12 weeks;
  5. At least one according to v1.1 criteria;
  6. Have adequate renal and hepatic function;
  7. Patients voluntarily joined the study and signed .

Exclusion criteria

Exclusion Criteria:

  1. With a history of any in the past 5 years, excluding cured cervical carcinoma in situ and melanoma skin cancer;
  2. Patients have major surgical procedures or radiotherapy / chemotherapy within 4 weeks before the first medication;
  3. History of immunodeficiency;
  4. cardiovascular diseases;
  5. Known or suspected interstitial lung disease;
  6. Known hereditary or acquired bleeding thrombotic tendency;
  7. Active hepatitis and liver cirrhosis;
  8. Known allergic history of the drug components of this protocol;
  9. History of neurological or psychiatric disorders.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
107 participants (estimated)

Study arms

  • Experimental
    Low-Dose Group

    Drug: SHR-A1811 Subcutaneous Injection · Drug: SHR-A1811 for Injection

  • Experimental
    Medium-Dose Group

    Drug: SHR-A1811 Subcutaneous Injection · Drug: SHR-A1811 for Injection

  • Experimental
    High-Dose Group

    Drug: SHR-A1811 Subcutaneous Injection · Drug: SHR-A1811 for Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the curve from time zero to 21 days (AUC0-21d) of SHR-A1811(sc)

    Time frame: About 72 weeks.

  2. The incidence and severity of Dose-Limiting Toxicities (DLTs)

    Time frame: About 72 weeks.

  3. Adverse Events (AEs)

    Time frame: About 72 weeks.

Secondary outcomes

  1. Time to maximum concentration (Tmax)

    Time frame: About 72 weeks.

  2. Maximum concentration (Cmax)

    Time frame: About 72 weeks.

  3. Trough concentration (Cmin)

    Time frame: About 72 weeks.

  4. Area under the concentration-time curve from time zero to the time of the last measurable concentration (AUC0-t)

    Time frame: About 72 weeks.

  5. Area under the concentration-time curve from time zero extrapolated to infinity (AUCinf)

    Time frame: About 72 weeks.

  6. Elimination half-life (t1/2)

    Time frame: About 72 weeks.

  7. Mean residence time (MRT)

    Time frame: About 72 weeks.

  8. Apparent clearance (CL/F)

    Time frame: About 72 weeks.

  9. Apparent volume of distribution at steady state (Vss/F)

    Time frame: About 72 weeks.

  10. Area under the concentration-time curve at steady state (AUCss)

    Time frame: About 72 weeks.

  11. Maximum concentration at steady state (Css, max)

    Time frame: About 72 weeks.

  12. Trough concentration at steady state (Css, min)

    Time frame: About 72 weeks.

  13. Accumulation ratio (Rac)

    Time frame: About 72 weeks.

  14. Anti-SHR-A1811 antibodies (ADA)

    Time frame: About 72 weeks.

  15. Objective Response Rate (ORR)

    Time frame: About 72 weeks.

  16. Duration of Response (DoR)

    Time frame: About 72 weeks.

  17. Disease Control Rate (DCR)

    Time frame: About 72 weeks.

  18. Progression-Free Survival (PFS)

    Time frame: About 72 weeks.

  19. Overall Survival (OS)

    Time frame: About 72 weeks.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Jun 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Dec 10, 2025
StartActual
Dec 23, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2027
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07275242
Responsible party
Sponsor
First posted
Dec 10, 2025
Start date
Dec 23, 2025
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jan 15, 2026

Study contacts

Yue Zhang
Contact
yue.zhang@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab rezetecan

Start the discussion